ALAMEDA, Calif.--(BUSINESS WIRE)--Sept. 6, 2006--Advanced Cell Technology, Inc. (OTCBB: ACTC) (ACT) announced today that it has settled a patent dispute involving certain nuclear transfer cloning patents and patent applications owned or licensed by the University of Massachusetts (UMass), Roslin Institute (Roslin), Geron Corporation (Nasdaq: GERN) (Geron), Start Licensing, Inc. (Start) and ACT. The dispute involved appeals to the U.S. District Court by ACT and UMass that sought to overturn rulings by the U.S. Patent and Trademark Office against ACT and UMass in patent interference numbers 104,746 and 105,192.
